News & Updates

Recurrence-free survival (RFS) is significantly longer with erdafitinib treatment than with intravesical chemotherapy in patients with papillary-only, high-risk nonmuscle-invasive bladder cancer (NMIBC) who had disease recurrence after bacillus Calmette–Guérin (BCG) therapy and were ineligible for radical cystectomy, according to a study.

A 52-week course of intensified androgen-deprivation therapy (ADT) appears to extend prostate-specific antigen progression-free survival (PSA-PFS) in patients with biochemically recurrent prostate cancer (BRPC) compared with ADT alone, without prolonging time to testosterone recovery, according to the phase III open-label PRESTO trial.

Patient use of self-adjusted nitrous oxide (N2O) at levels of 20 percent to 45 percent during transrectal prostate biopsy is safe and well tolerated, according to a study. Delivery of low-dose N2O is associated with reduced pain, but its effect on anxiety does not seem significant.

Consumption of commercially available alkaline water does not provide significant benefits, partially because of its negligible alkali content, over tap water for patients with uric acid and cystine urolithiasis, reports a study.

Unconsummated marriage (UCM) among heterosexual couples is typically caused by erectile dysfunction (ED) and vaginismus, according to a study, noting however that a strong psychological component plays a major role in many of these cases.

Testicular cancer survivors (TCSs) demonstrate similar health-related quality of life (HRQoL) to that of the general population at a median of 28 years since treatment initiation, reports a study.

The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.

In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).